Showing 2281-2290 of 2527 results for "".
- ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2477112/ProQR Therapeutics announced that it received orphan drug designation (ODD) from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H m
- Glaukos Completes Acquisition of Avedrohttps://modernod.com/news/glaukos-completes-acquisition-of-avedro/2477110/Glaukos announced that it has completed its previously announced acquisition of Avedro. In August, Glaukos agreed to acquire cross-linking company Avedro in an all-stock transaction. Under the terms of the
- New Test Aims to Make Eye Testing More Accessiblehttps://modernod.com/news/new-test-aims-to-make-eye-testing-more-accessible/2477096/Research that aims to prove easee’s online refraction test is as accurate as an in person exam has been published in the Journal of Medical Internet Research. Undertaken at the University Medical Center Utrecht, in the Netherla
- Biogen Gains Commercialization Rights to Anti-VEGF Biosimilar Candidates After Deal with Samsung Bioepishttps://modernod.com/news/samsung-bioepis-enters-into-commercialization-agreement-for-next-generation-biosimilar-candidates/2477072/Samsung Bioepis has entered into a new commercialization agreement with Biogen for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States, Canada, Europe, Japan, and Australia. SB11, a biosimilar candidate referencing Lucent
- New ECP and Parent Survey Shows the Significant Need for Myopia Educationhttps://modernod.com/news/new-ecp-and-parent-survey-shows-the-significant-need-for-myopia-education/2477070/One in four children in the United States is myopic, but according to The Harris Poll survey results released by CooperVision, only 33% of parents know what that term means,2 or how it can affect their children’s future eyesight. This corroborates the finding that 97% of ECPs agree par
- Trump to Nominate Stephen Hahn, Cancer Researcher, to Head FDAhttps://modernod.com/news/trump-to-nominate-stephen-hahn-cancer-researcher-to-head-fda/2477068/President Trump said Friday that he intended to nominate Stephen M. Hahn, MD, a top executive at The University of Texas M.D. Anderson Cancer Center, to be the next commissioner of the Food and Drug Administration, according to a
- Oyster Point Pharma Announces Pricing of Initial Public Offeringhttps://modernod.com/news/oyster-point-pharma-announces-pricing-of-initial-public-offering/2477064/Oyster Point Pharma announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share. The shares began trading on The Nasdaq Global Select Market on October 31, 2019 under the symbol “OYST.” All of the shares ar
- Allergan Issues Recall for Certain Lots of Xen 45https://modernod.com/news/allergan-issues-recall-for-certain-lots-of-xen-45/2477061/Allergan has initiated a voluntary recall of its XEN 45 glaucoma drainage device after a small number of units in an unreleased lot were observed to have trace amounts of polishing compounds that are used in the needle sleeve manufacturing process, according to a joint news release with ASCRS.
- Manufacturers, Providers Increasingly Rely on Premium Cataract Surgery Revenuehttps://modernod.com/news/manufacturers-providers-increasingly-rely-on-premium-cataract-surgery-revenue/2477057/The importance of premium cataract surgery to manufacturers, surgeons, and surgery centers alike grows, as reimbursements for cataract surgery under nationalized health care systems worldwide continue to decline, according to a Market Scope report. The reduction in cataract surgery reimbur
- Regenxbio Exercises Option for Global License for Use of SCS Microinjector in AAV Gene Therapy Deliveryhttps://modernod.com/news/regenxbio-exercises-option-for-global-license-for-use-of-scs-microinjector-in-aav-gene-therapy-delivery/2477053/Clearside Biomedical announced that Regenxbio has exercised its option under the previously announced option and license agreement to license Clearside’s proprietary, in-office SCS Microinjector for the delivery of adeno-associated virus (AAV)-based therapeutics, including but not